USPTO serial 79283673
ANACONDA
Reviewed by CopyMark Law Group
Reg. 6375090Status 404
- Filing date
- Status date
- Registration date
- Jun 8, 2021
- Examiner
- HOFFMAN, DAVID AARON
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ANACONDA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Thomas W. Cole
Thomas W. Cole Roberts Calderon Safran & Cole P.C.7918 Jones Branch Drive, Suite 500McLean, VA 22102UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Surgical apparatus and instruments for medical, dental and veterinary purposes; artificial vascular grafts, artificial stent grafts, artificial thoracic, aortic, thoracoabdominal and abdominal stent grafts, surgical hybrid stent grafts for treatment of thoracoabdominal aortic aneurysms, stents, and patches for repair and reconstruction of internal tissue; vascular prostheses; surgical implants comprising artificial materials; suture materials; grafts made primarily of artificial materials being patches for repair and/or reconstruction of internal tissue; implantable medical systems comprised of artificial endovascular stent grafts; implantable medical devices, namely, artificial endovascular stent grafts; implantable medical devices comprising an artificial graft and stent joined together and compacted into a delivery system; artificial vascular grafts; artificial branched vascular grafts; artificial endovascular grafts; surgical graft materials, namely, artificial vascular grafts and artificial endovascular grafts; medical systems, namely, stent delivery systems; medical devices comprising an artificial vascular graft and a stent; medical devices comprising an artificial vascular graft, a stent and a delivery system; medical systems and medical devices in the nature of surgical implants comprising artificial material and associated surgical instrument sets for use in endovascular procedures; medical systems and medical devices in the nature of surgical implants comprising artificial material and associated surgical instrument sets for use in thoracoabdominal procedures; medical systems and medical devices in the nature of surgical implants comprising artificial material and associated surgical instrument sets for use in aortic arch procedures; thoracic stents; artificial thoracic stent grafts; artificial stent grafts; artificial stent graft systems; artificial stent graft devices; artificial stent graft systems and surgical devices comprising more than one component; artificial stent graft systems and surgical devices comprising components of more than one stent graft; artificial stent graft systems and surgical devices comprising components of more than one type of stent graft; artificial thoracic stent graft systems; artificial thoracoabdominal stent graft systems; artificial thoracic stent graft devices; artificial thoracoabdominal stent graft devices; delivery systems for artificial stent graft systems and artificial stent graft devices; medical systems, namely, minimally invasive devices for aneurysm repair, including thoracoabdominal aortic aneurysm ('TAAA') repair; medical devices, namely, minimally invasive devices for aneurysm repair; including thoracoabdominal aortic aneurysm ('TAAA') repair; artificial cardiac valves for surgical prostheses; cardiac valve replacement systems, namely, artificial cardiac valves; artificial heart valves; artificial heart valve conduits; artificial cardiac patches; artificial vascular patches; artificial cardiovascular patches; artificial thoracic patches; artificial tissue patches; parts and fittings for all of the aforementioned goods | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 1, 2024 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Nov 1, 2024 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Oct 24, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 29, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 29, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 8, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 8, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 23, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 23, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 21, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 3, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 3, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 3, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 17, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 17, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 17, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 17, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 17, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 29, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 29, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 29, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 14, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 30, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 30, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 23, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 22, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 22, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 24, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 20, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 16, 2020 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |